

I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The...
You can purchase shares of Relmada Therapeutics (NASDAQ:RLMD) through any online brokerage.
Other companies in Relmada Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Relmada Therapeutics has a consensus price target of $10.00.
The stock price for Relmada Therapeutics (NASDAQ: RLMD) is $3.44 last updated October 29, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Relmada Therapeutics.
Relmada Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Relmada Therapeutics.
Relmada Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently...